DRGD 12th Revision: What Changed for Product Registration Holders in Malaysia
C. Y. Chin, Business Development Director | Infinity Pharmacare | September 2026
Two new clauses in the Drug Registration Guidance Document (DRGD) change who can hold a Malaysian marketing authorisation and what that entity may call itself. Section 5.1(e) allows government agencies and research or higher education institutions to establish subsidiary companies through their private wings to serve as Product Registration Holders and/or manufacturers, with a narrow exception permitting direct authorisation, without a subsidiary, where there is strong justification and urgent patient need. Section 5.1(f) prohibits private companies from using company names or acronyms that resemble the names of those institutions, to avoid confusion among consumers. Both are new standalone provisions. A narrower version of the naming restriction already existed, buried inside a longer list under Section 5.1(b) of the 11th Revision. The 12th Revision pulled it out and rebuilt it into these two dedicated clauses. Both took effect on 31 July 2026. If your Malaysian partner due diligence was completed before that date, it was run against a rulebook that no longer applies.
Most foreign manufacturers treat a DRGD revision as document housekeeping and delegate it to their local partner. This one deserves your own attention, for two reasons. It creates a new class of entity that can hold your registration, and it puts a standing restriction on the name of the company that holds it. The sequencing matters as much as the substance: NPRA issued a standalone circular on the naming restriction in April, then folded it into the DRGD text in July. That gap is a lesson in how Malaysian regulatory change actually reaches you.
This briefing assumes you already understand what a Product Registration Holder (PRH) is, why a foreign manufacturer cannot hold its own MAL, and how hard a registration is to move once someone else holds it. If any of that is new, read the foundation piece first. What follows is the update.
What changed in the DRGD 12th Revision for PRH eligibility?
Two clauses were added to Section 5.1, the part of the DRGD that sets out who may apply to hold a product registration.
Section 5.1(e) permits any government agency and research or higher education institution to establish subsidiary companies through their private wings, to serve as Product Registration Holders and/or manufacturers. A second sentence in the same clause allows these entities to act as PRH or manufacturer directly, without a subsidiary, but only with strong justification and urgent patient need, including national interest, emergency, or disaster situations. Section 5.1(f) prohibits any private company, other than a government agency or research or higher education institution, from using a company name or acronym that resembles one, to avoid confusion among consumers.
The instrument matters. The 12th Revision was mandated by Director’s Directive No. 18 of 2026 (Bil 18 Tahun 2026), signed by Wan Noraimi binti Wan Ibrahim, Director, National Pharmaceutical Regulatory Division. This is a directive from the division that regulates the register, not a consultation paper or a discussion draft. It carries an effective date of 31 July 2026 and applies from that date.
| Provision | DRGD 3rd Ed., 11th Revision (January 2026) | DRGD 3rd Ed., 12th Revision (July 2026) |
|---|---|---|
| Government agency and research or higher education institution as PRH | Not addressed | Section 5.1(e): may establish subsidiary companies through their private wings to serve as PRH and/or manufacturers |
| Restriction on institutional-sounding company names | Present narrowly, two of five prohibited name types under Section 5.1(b) | Removed from 5.1(b) and rebuilt as standalone Section 5.1(f), same restriction, now paired with an explicit carve-out for the institutions themselves under 5.1(e) |
| Instrument | Prior revision | Director’s Directive No. 18 of 2026 (Bil 18 Tahun 2026) |
| Effective date | January 2026 | 31 July 2026 |
Read side by side, the two clauses do one thing. They open a door for institutions and they close a door on private companies that were trading on institutional resemblance.
Why can government agencies and research institutions now hold a PRH?
Because the barrier was never institutional credibility. It was corporate form.
The existing eligibility test requires the applicant to be a locally incorporated company or legal entity registered with the Companies Commission of Malaysia (SSM), with a business scope related to health or pharmaceutical products. A ministry, a statutory body, a public research institute or a public university does not sit inside that description in its own right. The result was a class of Malaysian organisations that could generate a dossier and in some cases manufacture, but could not be the holder of record. Section 5.1(e) resolves that by naming the vehicle: a subsidiary company established through the institution’s private wing.
NPRA has not published a rationale statement alongside the clause, so treat the reasoning above as a reading of the text rather than an official explanation. The commercial consequence, however, is concrete. Malaysia has widened the pool of entities that can legally hold your MAL, and some of them come with local manufacturing capacity, clinical infrastructure, or a public sector relationship that a private distributor cannot match.
Now challenge the obvious conclusion. A government linked or university linked PRH is not automatically the safer choice. The lock-in problem described in our Change of Product Registration Holder analysis is form neutral. A transfer still has to be initiated by the outgoing holder, and it still depends on that holder’s board acting. An institutional subsidiary may have a slower, more committee driven approval chain than a private company, which is precisely the mechanism a transfer relies on. Institutional prestige does not shorten that path. Test governance and decision speed, not the letterhead.
What does the new naming restriction actually prohibit?
Any private company (other than a government agency or research or higher education institution) is prohibited under Section 5.1(f) from using a company name or acronym that resembles the name of such an institution, to avoid confusion among consumers.
The target is borrowed institutional credibility. A private company whose registered name or acronym reads as though it carries a government or university affiliation presents itself to the market, and to the register, as something it is not. The restriction attaches to the identity of the applicant entity, not to the quality of the dossier it files.
That has a direct due diligence consequence for anyone appointing or reviewing a Malaysian PRH. Three checks are worth running now. First, compare the candidate’s registered SSM name and its trading acronym against the names of Malaysian government agencies and public institutions. Second, if the name does carry an institutional resemblance, ask for documentary proof of the actual affiliation rather than accepting the implication. Third, treat an unexplained institutional-sounding name as a red flag on the entity itself, not merely a naming technicality, because it tells you something about how that partner positions itself.
There is no transition period. NPRA’s own circular states the effective date of implementation is immediate. A company already operating under an affected name has been exposed since the circular, not from some future compliance date. If a live PRH relationship is potentially caught, that is a present question, not one to defer to the next renewal cycle.
Why did NPRA issue a circular in April before codifying this in July?
Because the naming restriction was already in force months before it appeared in the DRGD text. NPRA issued a standalone circular addressing it on 14 April 2026. It was folded into the DRGD itself in the 12th Revision, effective 31 July 2026, roughly three and a half months later.
That sequence tells you how the Malaysian system actually moves. The DRGD is a consolidating document. It gathers requirements that in many cases are already operative, published earlier through circulars and directives. By the time a change reaches the guidance document, the market has usually been working to it for a quarter or more.
The decision implication is a monitoring one, and it is the part most foreign manufacturers get wrong. If your regulatory intelligence consists of checking the DRGD version number, you are structurally a quarter behind, and you will discover requirements at the point where they have already been applied to someone else’s submission. Circulars are the leading indicator. The DRGD is the lagging record.
Ask a specific question of whoever holds your Malaysian regulatory relationship: do you monitor NPRA circulars as issued, or do you report to me on DRGD revisions? The two answers describe very different levels of service. A partner who only forwards revision summaries is not giving you regulatory intelligence, they are giving you a changelog.
Does this affect an existing PRH relationship, or only new applications?
The two clauses behave differently, and the distinction drives what you do next.
Section 5.1(e) is permissive and forward looking. It enables a category of applicant that was previously outside the eligibility definition. Nothing in it requires action from a manufacturer whose registrations are already held by a private local PRH. Its relevance to you is strategic: a wider partner pool for new registrations, new local manufacturing conversations, and a new class of potential competitor for public sector supply.
Section 5.1(f) is prohibitive, and it attaches to a company name. A name is a standing attribute of an entity, not a one time test passed at the point of application. Read on its face, the clause is not limited to the moment of filing. That is the reading a prudent manufacturer should plan against, while confirming the position with NPRA rather than relying on inference.
| Your situation | Exposure under the 12th Revision | Action |
|---|---|---|
| Appointing a new PRH after 31 July 2026 | Both clauses apply to the eligibility assessment | Run the naming check before signing; widen the candidate list to include institutional subsidiaries where they add manufacturing or public sector value |
| Existing PRH, ordinary private company name | Low. Section 5.1(e) is enabling only | No action beyond noting the wider partner pool for future filings |
| Existing PRH whose name or acronym resembles a government agency or public institution | Caught by Section 5.1(f) with immediate effect, confirmed by NPRA’s own circular, no grace period exists | This is a current exposure, not a future one. Seek written clarification from NPRA now, not at your next renewal |
| Due diligence completed before July 2026 | Assessed against the 11th Revision, which contains neither clause | Re-run the eligibility and naming checks against the 12th Revision text |
| Considering a government or university linked subsidiary as PRH | Newly permitted under Section 5.1(e) | Test board composition and decision timelines, not institutional reputation, because transfers depend on the holder acting |
The through line is the one that has not changed. Whoever holds the MAL holds your market access. The 12th Revision alters who is allowed to be that entity and what it may be called. It does nothing to reduce the consequence of choosing badly.
Frequently Asked Questions
What is the DRGD 12th Revision and when did it take effect?
The Drug Registration Guidance Document, Third Edition, 12th Revision, was published in July 2026 and took effect on 31 July 2026. It was mandated by Director’s Directive No. 18 of 2026 (Bil 18 Tahun 2026), signed by Wan Noraimi binti Wan Ibrahim, Director, National Pharmaceutical Regulatory Division.
Can a government agency or public university be a Product Registration Holder in Malaysia?
Under new Section 5.1(e) of the 12th Revision, any government agencies and research or higher education institutions may establish subsidiary companies through their private wings to serve as Product Registration Holders (PRH) and/or manufacturers. The holder of record is the subsidiary company, not the institution itself.
What does Section 5.1(f) of the DRGD prohibit?
Any private company (other than a government agency or research or higher education institution) is prohibited from using a company name or acronym that resembles the name of a government agency or research or higher education institution, to avoid confusion among consumers.
Were these rules in the 11th Revision?
No. Neither Section 5.1(e) nor Section 5.1(f) appears in the DRGD Third Edition, 11th Revision of January 2026. Both are new in the 12th Revision.
Was the naming restriction announced before it entered the DRGD?
Yes. NPRA issued a standalone circular addressing the naming restriction on 14 April 2026, roughly three and a half months before it was formally incorporated into the DRGD text in July 2026.
Do these changes affect a PRH relationship that is already in place?
Section 5.1(e) is enabling and requires no action from manufacturers with an existing private PRH. Section 5.1(f) attaches to a company name, which is a standing attribute of the entity. There is no transition period. NPRA’s own circular states the effective date of implementation is immediate, so a PRH whose name resembles a government agency or public institution has been exposed since the circular and should seek written clarification from NPRA now, not at the next renewal.
This briefing is for general information only. It does not constitute legal, regulatory, or medical advice. Regulatory requirements change. Verify all details against current official NPRA guidance before making filing or commercial decisions.
If your Malaysian PRH arrangement was structured before 31 July 2026, the eligibility and naming position it was assessed against has changed. Talk to us about re-running that assessment against the 12th Revision, and about holding your registration through a PRH whose only interest is keeping your market access intact.